Internet and Psychiatry
  • Home
    • Editorials
    • Research news
    • Research papers
    • Interviews with eminent psychiatrists
    • Ten years ago
    • Fifteen years ago
  • Topics
    • Alcohol and Drug Abuse
    • Anxiety Disorders
    • Biomedical Science
    • Compulsive gambling
    • Disaster Medicine
    • Education
    • General Medicine
      • Acupuncture
      • Physical medicine and Rehabilitation
    • Human Rights
    • Interviews with eminent psychiatrists
    • Mood Disorders
      • Bipolar Disorder
      • Depression
      • Seasonal Affective Disorder
    • Neurological Disorders
    • Other Psychiatric Disorders
    • Posttraumatic Stress Disorder
    • Sexual Behavior
  • Books
    • Comorbidity of Depression and Alcohol Use Disorders
    • “Immigration and Mental Health” chapter abstracts
    • “Internet and Suicide” chapter abstracts
    • “Neurobiology of PTSD” chapter abstracts
    • “Suicidal Behavior in Alcohol…” chapter abstracts
    • “Suicide in the Military” chapter abstracts
    • “Terror and Suicide” chapter abstracts
    • “War and Suicide” chapter abstracts
  • Editors
    • Leo Sher, M.D.
    • Alexander Vilens, M.S.
  • Guests
    • Distinguished Guests
    • Our Contributors
  • Reflections
    • Poetry
    • Quotes

Editorials

CASIRIVIMAB and IMDEVIMAB {REGEN-COV}: 101 …Regeneron Pharmaceuticals’ monoclonal antibodies: a rescue pharmacotherapy for COVID-19…

October 25, 2021

Aya Allam, M.D., Steven Lippmann, M.D.

Besides all the pandemic talk these days, we hear lots about coronavirus treatment with monoclonal antibodies. There are many of them. What is the big deal?

Casirivimab and imdevimab are two monoclonal antibodies synthesized by the pharmaceutical company Regeneron, brand-named REGEN-COV. These dual proteins are a monoclonal antibodies intervention delivered parenterally to quickly provide a brief defense against severe coronavirus disease (COVID-19). At this, REGEN-COV is safe and effective.

The real answer to COVID-19 is a high percentage of fully vaccinated people. Otherwise, post-infection, recovered persons also have immunity especially when further augmented by a supplemental vaccination. Casirivimab and imdevimab remains primarily a rescue therapy for individuals particularly vulnerable to a coronavirus SARS-Co-V-2 infection.

This virus is very infectious and gains entry to cells via the angiotensin-converting enzyme-2. Once intracellular, it replicates and often causes cell destruction; the person then becomes sick. A high viral load can induce a damaging hyper-immunity with potential pulmonary and other poly-organ failures. COVID-19 is most dangerous to older and/or obese people and to most anyone with a wide variety of comorbidities and exposures.

The casirivimab and imdevimab monoclonal antibodies mimic the spike protein of the SARS-Co-V-2. That blocks cell receptors and yields protection by preventing virus entry into cells; that usually diminishes the seriousness of subsequent illness.

These two monoclonal antibodies are an approved pharmaceutical, administered under medical supervision and when a physician certifies that they are indicated in an individual case. Casirivimab and imdevimab are prescribed only in the very earliest stages of potential COVID-19 disease; the earlier the better. Not a preventative; it is an emergent intervention. Candidates include anyone over 12 years old and weighing over 40 kilograms. It can also be administered to someone soon after a viral exposure, if they test-result positive to virus presence, and have comorbidities of medical concern. This most especially applies to elderly persons and to those with immunocompromise. Casirivimab and imdevimab are not recommended for patients with severe COVID-19 disease, those hospitalized and/or receiving supplemental oxygen, even for those only requiring additional oxygen flow for pre-existing conditions.

Casirivimab and imdevimab is prepaid for those having Medicare or Medicaid. Financial costs might be anticipated for some insured patients and other people. A safe medication, it often attenuates COVID-19 disease, shortens the course of illness, and may avert death.

Related Posts

Editorials /

Monkeypox: A psychiatrist’s guide

Editorials /

Fluvoxamine attenuates COVID-19 disease

Editorials /

What? Botox injections can mitigate depressions?

‹ Clinical characteristics and psychiatric comorbidities in veterans with schizophrenia with or without suicidality › COVID-19: The neuropsychiatric sequela

Editorials

  • Monkeypox: A psychiatrist’s guide
  • Fluvoxamine attenuates COVID-19 disease
  • What? Botox injections can mitigate depressions?
  • Smoking, suicide risk, and the COVID-19 pandemic

Research Papers

  • COVID-19 mortality in Europe and the ’Iron Curtain’ between East and West
  • Examination of depressive signs and symptoms among 803 University students in seven Universities and Colleges. Hungary, Romania, Serbia.
  • Examination of spirituality and the dimensions of spirituality among 803 students in seven different Universities. Hungary, Romania and Serbia.
  • Examination of depressive signs and symptoms among 932 students in eight different secondary schools in Hungary

Research News

  • Brain-derived neurotrophic factor levels in combat veterans with or without a history of suicide attempt
  • Pro-inflammatory cytokines and suicidality in patients with bipolar disorder
  • Thirty years of publications in the field of suicidology
  • Osteoporosis drugs are associated with depression and anxiety

Latest News

  • Leading world experts on suicide. Expertscape, the June 20, 2022, report
  • The U.S. Department of Veterans Affairs offers large prizes for suicide prevention ideas
  • Suicide mortality in the U.S. decreased from 2018 to 2020 after increasing since 2000
  • The World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Men’s Mental Health – January 2022 update

Interviews with eminent psychiatrists

  • Interview with Professor Shih-Ku Lin
  • Interview with Professor Masahito Fushimi
  • Interview with Professor Maurizio Pompili
  • Interview with Professor Marco Sarchiapone

Ten Years Ago

  • Teaching medical professionals and trainees about suicide prevention
  • Suicidal ideation in depressed patients with or without comorbid posttraumatic stress disorder treated with selective serotonin reuptake inhibitors
  • Treatment of suicide attempters with bipolar disorder: a randomized clinical trial
  • Posttraumatic stress disorder and the Neuroevolutionary Time-depth Principle

Back to Top

  • About
  • Contact
  • Privacy Policy
  • Terms and Conditions
Copyright © 2022 AVCalc LLC. All rights reserved worldwide.